Total Funding
48
9
Total FundingPost-IPO Equity raised
Growth Score
-5 pts
Heat Score
-1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
245623
Asarina Pharma is a company targeted on developing products to treat women with severe symptoms associated with the menstrual cycle.
Peter Nordkild: Chief Executive Officer- Torbjorn Backstrom: Owner
About the Company
Asarina Pharma AB is a Swedish biotech company focusing on the development of Sepranolone (UC1010) for the treatment of premenstrual dysphoric disorder and other menstrually related conditions. The company's primary goal is to offer a novel therapy that is specifically designed for PMDD. Asarina has a second generation oral compound in
preclinical development for PMDD
